HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Chronic obliterative bronchiolitis — Clinical Guidelines

Overview

Chronic obliterative bronchiolitis (COB) is a progressive form of chronic lung allograft dysfunction that primarily affects lung transplant recipients, characterized by inflammation and fibrosis of the small airways leading to airflow obstruction and respiratory compromise. It significantly impacts long-term survival and quality of life post-transplantation. COB is one of the leading causes of morbidity and mortality in this patient population, underscoring its critical importance in clinical management and follow-up care 4 5 10. Understanding and effectively managing COB is crucial for optimizing outcomes in lung transplant recipients.

Pathophysiology

The pathogenesis of chronic obliterative bronchiolitis involves a complex interplay of immune and non-immune mechanisms. Initially, injury to the airway epithelium triggers an inflammatory response, often driven by both alloimmune reactions against the transplanted tissue and non-specific insults such as infections or gastroesophageal reflux 4 8. This inflammatory milieu promotes the recruitment of inflammatory cells, including macrophages and lymphocytes, which release cytokines and growth factors like transforming growth factor-β (TGFβ). Over time, these factors stimulate fibroblasts and smooth muscle cells, leading to excessive extracellular matrix deposition and fibrosis within the bronchioles 8 13. The fibrotic process results in luminal narrowing and eventual obliteration, manifesting clinically as progressive dyspnea and airflow limitation 4. Recent studies also highlight the role of microRNAs, such as miR-144, in dysregulating TGFβ signaling, further contributing to the fibrotic cascade 8.

Epidemiology

The incidence of chronic obliterative bronchiolitis varies but is estimated to affect up to 50% of lung transplant recipients within the first five years post-transplant 4 10. Risk factors include younger age at transplantation, longer duration of mechanical ventilation pre-transplant, and the presence of pre-existing lung disease such as idiopathic pulmonary fibrosis 4 9. Geographic and demographic variations are less emphasized in the literature, but certain immunosuppressive regimens and the frequency of surveillance bronchoscopies may influence its prevalence 3. Trends over time suggest improvements in immunosuppressive strategies and post-transplant care have modestly reduced incidence rates, though long-term outcomes remain suboptimal 9.

Clinical Presentation

Chronic obliterative bronchiolitis typically presents with a gradual onset of respiratory symptoms, including progressive dyspnea, cough, and wheezing. Patients may also experience exercise intolerance and recurrent respiratory infections due to compromised airway function 4. Red-flag features include unexplained decline in lung function tests (e.g., forced expiratory volume in one second [FEV1] decline >10%), hypoxemia, and increased respiratory effort. These symptoms often overlap with other forms of chronic lung allograft dysfunction, necessitating thorough diagnostic evaluation to confirm the diagnosis 4.

Diagnosis

The diagnosis of chronic obliterative bronchiolitis involves a combination of clinical assessment, imaging, and invasive procedures. Key diagnostic steps include:

Clinical Evaluation: Detailed history and physical examination focusing on respiratory symptoms and functional decline.

Pulmonary Function Tests (PFTs): Characteristic findings include a restrictive pattern with reduced lung volumes and a disproportionate decline in FEV1 compared to forced vital capacity (FVC).

High-Resolution Computed Tomography (HRCT): May show mosaic attenuation, bronchiolar wall thickening, and peribronchiolar inflammation.

Bronchoscopy with Bronchoalveolar Lavage (BAL) and Transbronchial Biopsy (TBB): Essential for histological confirmation of bronchiolitis obliterans (BO), characterized by submucosal fibrosis and obliteration of small airways.

Specific Criteria and Tests:

FEV1 Decline: ≥10% over 3 months or ≥15% over 6 months 4.

HRCT Findings: Mosaic attenuation, bronchiolar wall thickening, and peribronchiolar inflammation 3.

Histological Features: Submucosal fibrosis, obliterative changes in respiratory bronchioles 4 10.

Differential Diagnosis:

- Acute Rejection: Typically presents with acute onset symptoms and characteristic histopathological features. - Infectious Causes: Consider based on clinical context and BAL findings; specific pathogens identified through cultures and PCR. - Chronic Allergic Airway Disease: Often associated with eosinophilic inflammation and specific allergen triggers 4.

Management

First-Line Management

Optimization of Immunosuppression: Tailor immunosuppressive regimens to minimize rejection risk while avoiding over-immunosuppression, which can increase susceptibility to infections. Common agents include calcineurin inhibitors (e.g., tacrolimus), mTOR inhibitors (e.g., sirolimus), and corticosteroids.

- Tacrolimus: Target trough levels 5-10 ng/mL 1 6. - Sirolimus: Maintain trough levels 5-15 ng/mL 1 6. - Corticosteroids: Wean off if possible, monitor for adrenal insufficiency 1 6.

Second-Line Management

Anti-inflammatory Agents: Use of inhaled corticosteroids or bronchodilators to manage symptoms.

- Inhaled Corticosteroids: Fluticasone or budesonide, titrated based on response 1 6. - Bronchodilators: Short-acting (e.g., albuterol) or long-acting (e.g., salmeterol) as needed 1 6.

Refractory Cases / Specialist Escalation

Immunomodulatory Therapies: Consider novel agents like rituximab for BOS associated with donor-specific antibodies (DSAs).

- Rituximab: Administer at 375 mg/m2 weekly for 4 doses 13.

Lung Transplant Referral: For severe cases unresponsive to medical management, consideration of retransplantation may be necessary.

Pulmonary Rehabilitation: Enhance exercise tolerance and quality of life 1 6.

Monitoring and Follow-Up:

Regular PFTs every 3-6 months.

Surveillance bronchoscopies with BAL and TBB as per institutional protocols 3 10.

Complications

Infections: Increased susceptibility due to immunosuppression, requiring vigilant monitoring and prompt treatment.

Progression to Respiratory Failure: Advanced stages may necessitate mechanical ventilation support.

Quality of Life Decline: Progressive dyspnea and functional impairment impacting daily activities.

Referral Triggers: Unexplained decline in FEV1 >15%, persistent hypoxemia, or recurrent infections warrant specialist referral 4 10.

Prognosis & Follow-Up

The prognosis for patients with chronic obliterative bronchiolitis is generally guarded, with survival rates significantly reduced compared to those without BOS. Prognostic indicators include early onset of symptoms, rapid decline in lung function, and presence of donor-specific antibodies 4 10. Recommended follow-up intervals typically include:

Pulmonary Function Tests: Every 3-6 months.

Imaging and Bronchoscopy: Annually or as clinically indicated based on clinical decline 3 10.

Special Populations

Pediatric Patients: Limited data, but similar risk factors apply; close monitoring of growth and development alongside respiratory function is crucial 1 6.

Immunocompromised States: Additional vigilance for opportunistic infections; tailored immunosuppression balancing rejection risk and infection susceptibility 1 6.

Comorbidities: Presence of conditions like gastroesophageal reflux disease (GERD) or pre-existing lung injury may exacerbate COB progression; targeted management of these comorbidities is essential 4 10.

Key Recommendations

Regular surveillance with pulmonary function tests every 3-6 months to monitor for early signs of decline 4(Evidence: Strong).

Implement tailored immunosuppression regimens to minimize rejection risk while avoiding over-immunosuppression 1 6(Evidence: Strong).

Use high-resolution CT and bronchoscopy with BAL and biopsy for definitive diagnosis 3 10(Evidence: Strong).

Consider immunomodulatory therapies like rituximab in cases associated with donor-specific antibodies 13(Evidence: Moderate).

Initiate inhaled corticosteroids for symptom management in patients with significant airway inflammation 1 6(Evidence: Moderate).

Refer patients with unexplained FEV1 decline >15% or persistent hypoxemia for specialist evaluation 4 10(Evidence: Strong).

Regular follow-up bronchoscopies as per institutional protocols to monitor allograft status 3 10(Evidence: Strong).

Optimize management of comorbidities such as GERD to mitigate COB progression 4(Evidence: Moderate).

Consider pulmonary rehabilitation to improve exercise tolerance and quality of life 1 6(Evidence: Moderate).

Evaluate for retransplantation in refractory cases unresponsive to medical management 10(Evidence: Expert opinion).

References

1 Akkielah L, Leung W, Wang S, Ataie L, Xenocostas A, Syed A et al.. Concurrent Mold, Mycobacterial, and Viral Infections in a Hematopoietic Stem Cell Transplant Recipient Undergoing Lung Transplantation for Graft-Versus-Host Disease. Current oncology (Toronto, Ont.) 2026. link 2 Bondeelle L, Clément S, Bergeron A, Tapparel C. Lung stem cells and respiratory epithelial chimerism in transplantation. European respiratory review : an official journal of the European Respiratory Society 2025. link 3 Martinu T, Koutsokera A, Benden C, Cantu E, Chambers D, Cypel M et al.. International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2020. link 4 Di Carlo S, Rossi E, Politano G, Inghilleri S, Morbini P, Calabrese F et al.. Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study. PloS one 2016. link 5 Liu X, Yue Z, Yu J, Daguindau E, Kushekhar K, Zhang Q et al.. Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2016. link 6 Calarota SA, Chiesa A, De Silvestri A, Morosini M, Oggionni T, Marone P et al.. T-lymphocyte subsets in lung transplant recipients: association between nadir CD4 T-cell count and viral infections after transplantation. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2015. link 7 Salim H, Melendez J, Seethamraju H. Persistent hypoxemia and platypnea-orthodeoxia after left single-lung transplantation: a case report. Journal of medical case reports 2015. link 8 Xu Z, Ramachandran S, Gunasekaran M, Zhou F, Trulock E, Kreisel D et al.. MicroRNA-144 dysregulates the transforming growth factor-β signaling cascade and contributes to the development of bronchiolitis obliterans syndrome after human lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2015. link 9 Yang SM, Huang SC, Kuo SW, Huang PM, Pan SC, Lee JM et al.. Long-term outcome after bilateral lung transplantation - a retrospective study from a low-volume center experience. BMC surgery 2015. link 10 Mimura T, Walker N, Aoki Y, Manning CM, Murdock BJ, Myers JL et al.. Local origin of mesenchymal cells in a murine orthotopic lung transplantation model of bronchiolitis obliterans. The American journal of pathology 2015. link 11 Corris PA, Ryan VA, Small T, Lordan J, Fisher AJ, Meachery G et al.. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax 2015. link 12 Park H, Ko YB, Kwon HS, Lim CM. Bronchiolitis obliterans associated with Stevens-Johnson syndrome: a case report. Yonsei medical journal 2015. link 13 Xu Z, Nayak D, Yang W, Baskaran G, Ramachandran S, Sarma N et al.. Dysregulated MicroRNA Expression and Chronic Lung Allograft Rejection in Recipients With Antibodies to Donor HLA. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015. link 14 Ni D, Yu H, Zhang W, Gan L, Zhao J, Wang M et al.. A mouse model of interstitial pneumonitis induced by murine cytomegalovirus infection after allogeneic skin transplantation. BioMed research international 2013. link 15 Castleberry AW, Worni M, Kuchibhatla M, Lin SS, Snyder LD, Shofer SL et al.. A comparative analysis of bronchial stricture after lung transplantation in recipients with and without early acute rejection. The Annals of thoracic surgery 2013. link 16 Floreth T, Stern E, Tu Y, Stern R, Garrity ER, Bhorade SM et al.. Differentiated transplant derived airway epithelial cell cytokine secretion is not regulated by cyclosporine. Respiratory research 2011. link 17 Jonigk D, Merk M, Hussein K, Maegel L, Theophile K, Muth M et al.. Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs. The American journal of pathology 2011. link 18 Camagni S, D'Antiga L, Di Marco F, Grazioli L, Bonanomi E, Pinelli D et al.. Living Donor Lung Transplantation After Hematopoietic Stem Cell Transplantation From the Same Donor: A Risk Worth Taking. Chest 2024. link 19 Shimoyama K, Tsuchiya T, Watanabe H, Ergalad A, Iwatake M, Miyazaki T et al.. Donor and Recipient Adipose-Derived Mesenchymal Stem Cell Therapy for Rat Lung Transplantation. Transplantation proceedings 2022. link 20 Sheshadri A, Sacks NC, Healey BE, Raza S, Boerner G, Huang HJ. Lung Function Monitoring After Lung Transplantation and Allogeneic Hematopoietic Stem Cell Transplantation. Clinical therapeutics 2022. link 21 Müller C, Rosmark O, Åhrman E, Brunnström H, Wassilew K, Nybom A et al.. Protein Signatures of Remodeled Airways in Transplanted Lungs with Bronchiolitis Obliterans Syndrome Obtained Using Laser-Capture Microdissection. The American journal of pathology 2021. link 22 Morrone C, Smirnova NF, Jeridi A, Kneidinger N, Hollauer C, Schupp JC et al.. Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome. The European respiratory journal 2021. link 23 Lawaetz Schultz HH, Møller CH, Møller-Sørensen H, Mortensen J, Lund TK, Andersen CB et al.. Variation in Time to Peak Values for Different Lung Function Parameters After Double Lung Transplantation. Transplantation proceedings 2020. link 24 Zhang Z, Ding H, Liu F, Chen J. Successful bilateral lung transplantation and simultaneous Nuss technique correction of pectus excavatum post-allogeneic haematopoietic stem cell transplantation. Interactive cardiovascular and thoracic surgery 2020. link 25 Chen-Yoshikawa TF, Sugimoto S, Shiraishi T, Minami M, Matsuda Y, Chida M et al.. Prognostic Factors in Lung Transplantation After Hematopoietic Stem Cell Transplantation. Transplantation 2018. link 26 Benden C, Haughton M, Leonard S, Huber LC. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2017. link 27 Ishii T, Bandoh S, Kanaji N, Tadokoro A, Watanabe N, Imataki O et al.. Air-leak Syndrome by Pleuroparenchymal Fibroelastosis after Bone Marrow Transplantation. Internal medicine (Tokyo, Japan) 2016. link 28 Robinson PD, Spencer H, Aurora P. Impact of lung function interpretation approach on pediatric bronchiolitis obliterans syndrome diagnosis after lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2015. link 29 Yung GL, Craig V. Lung transplantation and extracorporeal photopheresis: The answer to bronchiolitis obliterans?. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2015. link 30 Budding K, van de Graaf EA, Paantjens AW, Kardol-Hoefnagel T, Kwakkel-van Erp JM, van Kessel DA et al.. Profiling of peripheral blood mononuclear cells does not accurately predict the bronchiolitis obliterans syndrome after lung transplantation. Transplant immunology 2015. link 31 Heijink IH, Rozeveld D, van der Heide S, van der Bij W, Bischoff R, van Oosterhout AJ et al.. Metalloproteinase Profiling in Lung Transplant Recipients With Good Outcome and Bronchiolitis Obliterans Syndrome. Transplantation 2015. link 32 Krustrup D, Iversen M, Martinussen T, Schultz HH, Andersen CB. The number of FoxP3+ cells in transbronchial lung allograft biopsies does not predict bronchiolitis obliterans syndrome within the first five years after transplantation. Clinical transplantation 2015. link 33 García Sáez D, Mohite PN, Zych B, Sabashnikov A, Moza A, Carby M et al.. Bilateral lung transplantation in a patient with Vascular Ehlers-Danlos syndrome. The Annals of thoracic surgery 2014. link 34 Willner DL, Hugenholtz P, Yerkovich ST, Tan ME, Daly JN, Lachner N et al.. Reestablishment of recipient-associated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome. American journal of respiratory and critical care medicine 2013. link 35 Lyu DM, Grazia TJ, Benson AB, Cagle LR, Freed BM, Zamora MR. Pre-transplant presence of antibodies to MICA and HLA class I or II are associated with an earlier onset of bronchiolitis obliterans syndrome in lung transplant recipients. Clinical transplants 2012. link 36 Treede H, Glanville AR, Klepetko W, Aboyoun C, Vettorazzi E, Lama R et al.. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2012. link 37 Kastelijn EA, van Moorsel CH, Rijkers GT, Ruven HJ, Karthaus V, Kwakkel-van Erp JM et al.. Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2010. link 38 Benden C, Boehler A. Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 2009. link 39 Sato M, Hirayama S, Hwang DM, Lara-Guerra H, Wagnetz D, Waddell TK et al.. The role of intrapulmonary de novo lymphoid tissue in obliterative bronchiolitis after lung transplantation. Journal of immunology (Baltimore, Md. : 1950) 2009. link 40 Hodge S, Holmes M, Banerjee B, Musk M, Kicic A, Waterer G et al.. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009. link 41 Madill J, Aghdassi E, Arendt B, Hartman-Craven B, Gutierrez C, Chow CW et al.. Lung transplantation: does oxidative stress contribute to the development of bronchiolitis obliterans syndrome?. Transplantation reviews (Orlando, Fla.) 2009. link 42 Maury G, Langer D, Verleden G, Dupont L, Gosselink R, Decramer M et al.. Skeletal muscle force and functional exercise tolerance before and after lung transplantation: a cohort study. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008. link 43 Hartwig MG, Snyder LD, Appel JZ, Cantu E, Lin SS, Palmer SM et al.. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2008. link 44 Burton CM, Iversen M, Scheike T, Carlsen J, Andersen CB. Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies. Transplantation 2008. link 45 Fietta AM, Meloni F. Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome. Current medicinal chemistry 2008. link 46 Van Muylem A, Knoop C, Estenne M. Early detection of chronic pulmonary allograft dysfunction by exhaled biomarkers. American journal of respiratory and critical care medicine 2007. link 47 McNeil K, Glanville AR, Wahlers T, Knoop C, Speich R, Mamelok RD et al.. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006. link 48 Sano Y, Date H, Nagahiro I, Aoe M, Shimizu N. Living-donor lobar lung transplantation for bronchiolitis obliterans after bone marrow transplantation. The Annals of thoracic surgery 2005. link 49 Allen DJ, Fildes JE, Yonan N, Leonard CT. Changes in induced sputum in the presence of bronchiolitis obliterans syndrome and correlation with spirometry in single and bilateral lung transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2005. link 50 Silverborn M, Ambring A, Nilsson F, Friberg P, Jeppsson A. Increased arterial stiffness in cyclosporine-treated lung transplant recipients early after transplantation. Clinical transplantation 2004. link 51 Li S, Louis LB, Kawaharada N, Yousem SA, Pham SM. Intrathymic inoculation of donor bone marrow induces long-term acceptance of lung allografts. The Annals of thoracic surgery 2003. link04287-x) 52 Wilkes DS, Bowman D, Cummings OW, Heidler KM. Allogeneic bronchoalveolar lavage cells induce the histology and immunology of lung allograft rejection in recipient murine lungs: role of intercellular adhesion molecule-1 on donor cells. Transplantation 1999. link 53 Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. Journal of immunology (Baltimore, Md. : 1950) 1994. link 54 Sakiyama S, Uyama T, Tanida N, Fukumoto T, Nagasawa H, Himeno K et al.. Pathogenesis of late airway changes in long-term surviving lung allografts. American journal of respiratory and critical care medicine 1994. link 55 Wood ML, Monaco AP. The effect of cyclophosphamide on the splecific unresponsiveness to skin allografts induced in ALS-treated mice infused with donor bone marrow. Journal of immunology (Baltimore, Md. : 1950) 1977. link

Chronic obliterative bronchiolitis